SCHEMBL4485069

SCHEMBL4485069

C=CC[C@H](C(N)=O)[C@@H](CC1CCCC1)C(=O)NC1CN(c2ccccc2)c2ccccc2N(Cc2cccc(-c3ccc4ccccc4c3)c2)C1=O

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ XIAP P98170 14/20 0.42
▸ PSEN1 P49768 1/20 0.39
▸ PSEN2 P49810 1/20 0.39
▸ APH1B Q8WW43 1/20 0.39
▸ NCSTN Q92542 1/20 0.39
▸ APH1A Q96BI3 1/20 0.39
▸ PSENEN Q9NZ42 1/20 0.39
▸ APP P05067 1/20 0.37
▸ NPY1R P25929 2/20 0.37
▸ NOTCH1 P46531 1/20 0.36
▸ RBPJ Q06330 1/20 0.36
▸ CYP3A4 P08684 1/20 0.35
▸ MME P08473 1/20 0.35
▸ ACE P12821 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4489231 0.99 XIAP (0.42) XIAPPSEN1PSEN2APH1BNCSTN
SCHEMBL4487691 0.97 XIAP (0.43) XIAPPSEN1PSEN2APH1BNCSTN
SCHEMBL5618893 0.92 XIAP (0.47) XIAPPSEN1PSEN2APH1BNCSTN
SCHEMBL4498794 0.92 XIAP (0.44) XIAPPSEN1PSEN2APH1BNCSTN
SCHEMBL4501008 0.91 PSEN1 (0.47) XIAPPSEN1PSEN2APH1BNCSTN
SCHEMBL4484214 0.91 XIAP (0.47) XIAPPSEN1PSEN2APH1BNCSTN
SCHEMBL4477997 0.90 XIAP (0.44) XIAPPSEN1PSEN2APH1BNCSTN
SCHEMBL4487524 0.90 XIAP (0.43) XIAPPSEN1PSEN2APH1BNCSTN
SCHEMBL4487352 0.90 NOTCH1 (0.46) XIAPPSEN1PSEN2APH1BNCSTN
SCHEMBL4471421 0.90 PSEN1 (0.43) XIAPPSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7304056-B2 Succinoylamino lactams as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-12-04 — — US claimed
US-20060264417-A1 Succinoylamino lactams as inhibitors of a-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2006-11-23 — — US claimed
US-20050245501-A1 Succinoylamino lactams as inhibitors of A-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-11-03 — — US claimed
US-20030134841-A1 Succinoylamino lactams as inhibitors of A-beta protein production OLSON RICHARD E (US) 2003-07-17 — — US claimed
US-7507815-B2 Succinoylamino lactams as inhibitors of a-β protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2009-03-24 — — US disclosed
US-20080293692-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-11-27 — — US disclosed
US-7304055-B2 Succinoylamino lactams as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-12-04 — — US disclosed
US-7304056-B2 Succinoylamino lactams as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-12-04 — — US disclosed
US-20060264417-A1 Succinoylamino lactams as inhibitors of a-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2006-11-23 — — US disclosed
US-20060258638-A1 Succinoylamino lactams as inhibitors of A-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2006-11-16 — — US disclosed
US-7101870-B2 Succinoylamino lactams as inhibitors of A-β protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2006-09-05 — — US disclosed
US-6962913-B2 Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB COMPANY (US) 2005-11-08 — — US disclosed
US-20050245501-A1 Succinoylamino lactams as inhibitors of A-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-11-03 — — US disclosed
US-6794381-B1 BETA -PEPTIDE INHIBITOR PREVENTS NEUROLOGICAL DEPOSITS OF AMYLOID PRECURSOR PROTEIN; ALZHEIMER'S DISEASE AND DOWN'S SYNDROME TREATMENT BRISTOL-MYERS SQUIBB COMPANY 2004-09-21 — — US disclosed
US-20030134841-A1 Succinoylamino lactams as inhibitors of A-beta protein production OLSON RICHARD E (US) 2003-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264417-A1 Succinoylamino lactams as inhibitors of a-beta protein production BACE1, APH1A, APP XIAP 559/4885PSEN1 7/4885PSEN2 9/4885
US-20080293692-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION BACE1, APH1A, APP XIAP 559/4885PSEN1 7/4885PSEN2 9/4885
US-20050245501-A1 Succinoylamino lactams as inhibitors of A-beta protein production BACE1, APH1A, APP XIAP 559/4885PSEN1 7/4885PSEN2 9/4885
US-20060258638-A1 Succinoylamino lactams as inhibitors of A-beta protein production BACE1, APH1A, APP XIAP 559/4885PSEN1 7/4885PSEN2 9/4885
US-20030134841-A1 Succinoylamino lactams as inhibitors of A-beta protein production APH1A, BACE1, APP XIAP 602/4885PSEN1 7/4885PSEN2 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback